| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $85.2M | — |
| R&D Expense | $195.7M | +38.5% |
| SG&A Expense | $49.1M | +5.3% |
| Operating Income | -$159.5M | +15.1% |
| Income Tax | $0 | — |
| Net Income | -$140.1M | +12.9% |
| EPS (Basic) | -$2.42 | +18.8% |
| EPS (Diluted) | -$2.42 | +18.8% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $60.2M | -59.7% |
| Short-term Investments | $342.4M | +24.3% |
| Current Assets | $413.1M | -5.0% |
| Total Assets | $566.7M | +1.1% |
| Current Liabilities | $44.0M | +50.9% |
| Total Liabilities | $61.0M | +22.6% |
| Stockholders' Equity | $505.7M | -1.0% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$109.1M | +18.9% |
| Capital Expenditures | $536K | -85.8% |
| Investing Cash Flow | -$93.0M | +69.3% |
| Financing Cash Flow | $113.0M | -66.5% |
| Free Cash Flow | -$109.6M | +20.8% |